Anti‐CD19 chimeric antigen T cell (CAR‐T) therapy has been shown to be effective in both prevention and treatment in preclinical SLE mouse models [292, 293], and similar satisfactory results have been reported in both adult and pediatric patients [183, 184, 185]. The gene discussed is CD19; the disease is systemic lupus erythematosus.